Heparin albumin containing adsorbents for hemoperfusion
Ukrainian R&D center offers new hemoadsorbent for clinical application comprising nanostructured carbon matrix ,immobilised albumin and heparin for removal of bilirubin, bile acids, bacterial endotoxin, anti-inflammatory cytokines with hydrophobic toxins and DNA-tropic components from blood. This hemoadsorbent enhances biocompatibility and increases its adsorptive capacity towards aforementioned substances. Looking for industrial partners and universities for research cooperation.
Type of partner sought - research centers, universities, big pharmaceutical companies for joint preclinical and clinical studies. Different collaboration options including research cooperation agreement are available depending on the partners' expertise. Specific area of activity - Healthcare, pharmaceutical products, medical biomaterial. Tasks – Research centers, universities, pharmaceutical companies for joint further development of the new coated nanostructured hemosorbent.
The technology was developed in Ukrainian academic research center, which was established in 1960 and is a part of Ukrainian Academy of Sciences Preliminary studies on development of heparin- protein-carbon adsorbent with a permeable coating demonstrated very high adsorptive capacity towards unconjugated bilirubin (more than 200 mg/g of carbon matrix) (Fig.1) that is several times higher than the capacity of state-of-the-art deligandizing hemoadsorbents. Heparin presence in the coating not only enhances biocompatibility but attaches selectivity to hemoadsorbents towards heparin (DNA) –binding proteins as anti-ss-DNA and anti-n-DNA antibodies . Selectivity of heparin containing charcoal to anti-ss-DNA AT 1.5 0.2( n=19) is significantly higher than those of uncoated charcoal 1.10.2 (n=31), idem for anti-n-DNA AT 1.60.18 (n=6) and 1.0 0.18(n=6). Albumin-heparin containing hemoadsorbents will be developed and tested in vitro, in vivo systems (preclinical studies). This adsorbent disposable in plastic columns (200 cc and 400 cc capacities) will be applied for treatment of acute and chronic hepatic insufficiencies and in cases of intoxication with hydrophobic poisons. Looking for research centers, universities, big pharmaceutical companies for joint preclinical and clinical studies. Different collaboration options including research cooperation agreement are available depending on the partners' expertise.
Advantages and innovations
Preliminary studies of adsorptive capacity towards unconjugated bilirubin of albumin-heparin containing hemoadsorbents show that it is 3-5 times higher than the best existing international analogues.
Under development/lab tested
Intellectual Property Rights (IPR)
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below